{"nctId":"NCT00984867","briefTitle":"Dapagliflozin DPPIV Inhibitor add-on Study","startDateStruct":{"date":"2009-10"},"conditions":["Type 2 Diabetes"],"count":833,"armGroups":[{"label":"1","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dapagliflozin"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Dapagliflozin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with type 2 diabetes\n* Patients who are not receiving treatment , or those who currently receive metformin, sitagliptin or vildagliptin or the combination of these\n* Patients will be screened by a blood test and only those who need additional therapy can be enrolled\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes\n* Patients with very poorly controlled diabetes\n* Any clinically significant illness, which in the judgement of the investigator would compromise the patient's safety or successful participation in the clinical study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To compare the change from baseline in HbA1c after 24 weeks treatment (LOCF) between dapagliflozin and placebo in patients with type 2 diabetes who are inadequately controlled on sitagliptin alone or on sitagliptin plus metformin.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"0.0509"},{"groupId":"OG001","value":"-0.45","spread":"0.0509"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight","description":"To compare the change in total body weight achieved with dapagliflozin versus placebo from baseline to week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.26","spread":"0.1741"},{"groupId":"OG001","value":"-2.14","spread":"0.1745"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in HbA1c in Participants With Baseline HbA1c ≥8%","description":"To compare the change in HbA1c in participants with baseline HbA1c ≥8% achieved with dapagliflozin versus placebo from baseline to week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":"0.0775"},{"groupId":"OG001","value":"-0.80","spread":"0.0797"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG)","description":"To compare the change in FPG achieved with dapagliflozin versus placebo from baseline to week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.81","spread":"2.3474"},{"groupId":"OG001","value":"-24.11","spread":"2.3474"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Seated Systolic Blood Pressure (SBP) in Participants With Baseline SBP>=130 mmHg","description":"To compare the change in seated systolic blood pressure (SBP) in participants with baseline seated SBP \\>=130 achieved with dapagliflozin versus placebo from baseline to week 8.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.12","spread":"1.0211"},{"groupId":"OG001","value":"-5.98","spread":"1.0638"}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in 2-hour Post Liquid Meal Glucose Rise","description":"To compare the change in 2-hour post liquid meal glucose rise achieved with dapagliflozin versus placebo from baseline to week 24.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.84","spread":"2.5098"},{"groupId":"OG001","value":"-21.65","spread":"2.4604"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving a Therapeutic Glycemic Response Defined as a Reduction in HbA1c of ≥0.7% Compared to Baseline","description":"To compare the proportion of participants achieving a therapeutic glycaemic response, defined as a reduction in HbA1c of ≥0.7% compared to baseline, with dapagliflozin versus placebo at week 24. Least Squares Mean represents the percent of participants adjusted for HbA1c baseline value.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":"2.491"},{"groupId":"OG001","value":"35.3","spread":"3.083"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":226},"commonTop":["Nasopharyngitis"]}}}